X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12) 12
humans (11) 11
aged (10) 10
female (10) 10
male (10) 10
middle aged (9) 9
diabetes (8) 8
risk factors (8) 8
abridged index medicus (7) 7
cardiovascular disease (7) 7
clinical trials (7) 7
double-blind method (7) 7
medicine, general & internal (7) 7
risk (7) 7
stroke (7) 7
cardiovascular diseases (6) 6
diabetes mellitus (6) 6
cardiac & cardiovascular systems (5) 5
double-blind (5) 5
drug therapy, combination (5) 5
follow-up studies (5) 5
mortality (5) 5
myocardial infarction (5) 5
myocardial-infarction (5) 5
rivaroxaban (5) 5
aspirin (4) 4
benzimidazoles - therapeutic use (4) 4
benzoates - therapeutic use (4) 4
blood pressure (4) 4
cardiovascular diseases - mortality (4) 4
diabetes mellitus, type 2 - drug therapy (4) 4
disease (4) 4
drug therapy (4) 4
health risks (4) 4
hypoglycemic agents - therapeutic use (4) 4
incidence (4) 4
insulin glargine (4) 4
insulin, long-acting - therapeutic use (4) 4
medicin och hälsovetenskap (4) 4
amputation (3) 3
angiotensin ii type 1 receptor blockers - therapeutic use (3) 3
angiotensin-converting enzyme inhibitors - adverse effects (3) 3
angiotensin-converting enzyme inhibitors - therapeutic use (3) 3
anticoagulants (3) 3
benzimidazoles - adverse effects (3) 3
benzoates - adverse effects (3) 3
cardiovascular diseases - drug therapy (3) 3
cerebral infarction (3) 3
cholesterol (3) 3
combination (3) 3
complications (3) 3
complications and side effects (3) 3
creatinine - blood (3) 3
death (3) 3
disease control (3) 3
endocrinology & metabolism (3) 3
fatty acids, omega-3 - therapeutic use (3) 3
glucose (3) 3
health risk assessment (3) 3
heart diseases (3) 3
insulin (3) 3
kidneys (3) 3
life sciences (3) 3
motivation (3) 3
patient outcomes (3) 3
patients (3) 3
peripheral artery disease (3) 3
prevention (3) 3
ramipril - adverse effects (3) 3
ramipril - therapeutic use (3) 3
risk analysis (3) 3
risk-factors (3) 3
telmisartan (3) 3
agonists (2) 2
analysis (2) 2
angiotensin ii type 1 receptor blockers - adverse effects (2) 2
antithrombotic therapy (2) 2
base-line (2) 2
blood glucose - drug effects (2) 2
cardiovascular diseases - prevention & control (2) 2
clinical outcomes (2) 2
clopidogrel (2) 2
converting enzyme-inhibitors (2) 2
coronary artery disease (2) 2
coronary vessels (2) 2
creatinine (2) 2
dextrose (2) 2
diabetes mellitus - drug therapy (2) 2
diabetes mellitus, type 2 - complications (2) 2
diabetes therapy (2) 2
diabetes-mellitus (2) 2
drugs (2) 2
events (2) 2
fatty acids (2) 2
glomerular filtration rate - drug effects (2) 2
glucagon (2) 2
glucagon-like peptide 1 (2) 2
glucose metabolism (2) 2
health aspects (2) 2
heart attacks (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9638, pp. 547 - 553
Summary Background Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors are known to reduce proteinuria. Their combination... 
Internal Medicine | COOPERATE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | RENIN-ANGIOTENSIN SYSTEM | DISEASE | PROTEINURIA | CONVERTING ENZYME-INHIBITORS | COMBINATION | NEPHROPATHY | II RECEPTOR BLOCKERS | PROGRESSION | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Ramipril - administration & dosage | Proteinuria - chemically induced | Cardiovascular Diseases - complications | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Benzimidazoles - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Benzimidazoles - therapeutic use | Kidney - drug effects | Double-Blind Method | Diabetes Mellitus - drug therapy | Proteinuria - metabolism | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Creatinine - urine | Benzoates - administration & dosage | Creatinine - blood | Aged | Urine | Drugs | Studies | Kidneys | Disease | Clinical trials | Risk | ACE inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2011, Volume 10, Issue 1, pp. 43 - 53
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2018, Volume 71, Issue 20, pp. 2306 - 2315
Background: Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse cardiovascular events (MACE) and major adverse... 
amputation | peripheral artery disease | antithrombotic therapy | death | major adverse limb events | Mortality | Analysis | Intervention | Anticoagulants | Stroke | Prognosis | Complications | Heart surgery | Angioplasty | Health risks | Risk | Cardiovascular disease | Hospitalization | Patients | Incidence | Vascular diseases | Ischemia | Coronary vessels | Amputation | Cardiovascular diseases
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2008, Volume 358, Issue 15, pp. 1547 - 1559
This large trial compared the angiotensin-receptor blocker telmisartan, the angiotensin-converting–enzyme inhibitor ramipril, and combination therapy with both... 
MEDICINE, GENERAL & INTERNAL | DESIGN | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | DOUBLE-BLIND | SYSTOLIC DYSFUNCTION | RANDOMIZED CLINICAL-TRIALS | CONGESTIVE-HEART-FAILURE | COMBINATION | CONVERTING-ENZYME-INHIBITORS | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Risk | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Diabetes Mellitus - drug therapy | Kaplan-Meier Estimate | Hospitalization | Creatinine - blood | Angioedema - chemically induced | Aged | Complications and side effects | Ramipril | Drug therapy, Combination | Diabetes | Cardiovascular diseases | Drug therapy | Comparative analysis | Risk factors | Telmisartan | Clinical trials | Vein & artery diseases | Cardiovascular disease | Pharmacology | Clinical outcomes | Index Medicus | Abridged Index Medicus | Blood Pressure | Benzimidazoles | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | epidemiology | Angiotensin-Converting Enzyme Inhibitors | Combination | MEDICAL AND HEALTH SCIENCES | Creatinine | chemically induced | Benzoates | drug therapy | Angioedema | drug effects | Diabetes Mellitus | blood | adverse effects | mortality | therapeutic use | Kaplan-Meiers Estimate
Journal Article
by Connolly, Stuart J and Eikelboom, John W and Bosch, Jackie and Dagenais, Gilles and Dyal, Leanne and Lanas, Fernando and Metsarinne, Kaj and O'Donnell, Martin and Dans, Anthony L and Ha, Jong-Won and Parkhomenko, Alexandr N and Avezum, Alvaro A and Lonn, Eva and Lisheng, Liu and Torp-Pedersen, Christian and Widimsky, Petr and Maggioni, Aldo P and Felix, Camilo and Keltai, Katalin and Hori, Masatsugu and Yusoff, Khalid and Guzik, Tomasz J and Bhatt, Deepak L and Branch, Kelley R H and Cook Bruns, Nancy and Berkowitz, Scott D and Anand, Sonia S and Varigos, John D and Fox, Keith A A and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and RECH, RAFAEL and ... and COMPASS Investigators and COMPASS investigators
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 205 - 218
Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of... 
PREVENTION | MEDICINE, GENERAL & INTERNAL | ORAL RIVAROXABAN | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Coronary Artery Disease - drug therapy | Morbidity | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Anticoagulants | Aspirin | Stroke | Heart attacks | Mortality | Coronary artery | Clinical trials | Cardiovascular disease | Coronary artery disease | Disease control | Disease prevention | Coronary vessels | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 05/2019, Volume 156, Issue 6, pp. S-173 - S-174
Journal Article
Gastroenterology, ISSN 0016-5085, 05/2019, Volume 156, Issue 6, pp. S-174 - S-174
Journal Article